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Abstract 23 
 24 
Discovery of small molecule modulators of signalling pathways is currently a particularly 25 
active area of research. We aimed at developing unprecedented metal-based activators of Akt 26 
signalling, which can potentially find applications as tools for regulating glucose metabolism 27 
downstream of Akt or serve as lead structures for developing anti-diabetic drugs. In this 28 
context, a highly diverse library of eleven new zinc(II) complexes with phenolic, picolinic, 29 
pyridino and hydroxamic ligands, all containing features beneficial for medicinal purposes, 30 
was prepared and screened in an assay that detected levels of phospho-Akt in lysates from 31 
NIH3T3 cells after treatment with the compounds. The complexes featuring hydroxamic-32 
based ligands were found to be the most prominent activators of Akt among the prepared 33 
molecules, with the most efficient compound (11) acting at sub-micromolar concentrations. 34 
Further characterisation revealed that this compound induces phosphorylation of the Akt 35 
downstream effector glycogen synthase kinase 3β (GSK3β), but does not act as an inhibitor 36 
of tyrosine phosphatases or PTEN.  37 
38 
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Introduction 39 
Small molecules with the ability to modulate cellular signalling have the potential to act as 40 
spatial and temporal perturbagens of biological processes, and thus constitute a reversible, 41 
practical, easily tuned and readily accessible alternative to genetic mutations in our study of 42 
biological systems.
[1]
 Using chemical tools to interfere with processes that involve protein 43 
phosphorylation, for example, has a high likelihood of leading to significant biological 44 
consequences (both structural and functional),
[2]
 since it is now well established that in all 45 
living systems phosphorylation serves as a universal signal that marks the activation or 46 
deactivation of enzymes and signalling cascades.
[3]
  47 
 48 
A particularly appealing target for modulation is the serine/threonine kinase Akt. The 49 
activation of Akt (Figure 1) is due to the phosphorylation of two sites (Thr-308 and Ser-473) 50 
by protein kinases that are controlled by phosphoinositide-3-kinase (PI3K).
[4]
 PI3K is 51 
activated by upstream signals such as insulin binding to its receptor. Numerous reports have 52 
linked Akt phosphorylation to critical biological events such as cell growth, proliferation and 53 
survival,
[5]
 thus rendering it medicinally significant for cancer
[6]
 and neurological diseases
[7]
 54 
among others. Akt activation has also been implicated in cellular glucose uptake and 55 
utilization, consequently Akt is also a highly relevant target in the development of anti-56 
diabetic drugs.
[8]
  57 
 58 
Identification of new small molecules that make it possible to regulate at will the 59 
phosphorylation levels of Akt might yield control over some of these downstream processes. 60 
With a focus on the diabetes implications of Akt activation, we have previously shown that a 61 
series of vanadium(IV) and vanadium(V) complexes with picolinic ligands were able to 62 
induce Akt phosphorylation, acting by inhibiting PTEN phosphatase, an enzyme upstream of 63 
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Akt that directly counteracts the function of PI3K.
[8a]
 In parallel, other laboratories have 64 
suggested that protein tyrosine phosphatases (PTP) are possible targets for complexes of 65 
vanadium.
[9]
 Recent studies by Sakurai describing metal-based small molecules with the 66 
ability to enhance Akt phosphorylation levels have involved zinc(II) as the metal center.
[10]
 67 
Most of these reports have suggested that zinc(II) complexes carry out their effects in a PI3K-68 
dependent mode,
[11]
 and that relatively high concentrations of complexes are needed in order 69 
to achieve significant Akt phosphorylation enhancements.  70 
 71 
 72 
Figure 1. Simplified schematic representation of the biochemical pathways that connect the insulin 73 
receptor (IR), PI3K and PTEN with Akt and its downstream effector GSK3β. 74 
 75 
Encouraged by the above findings and given the relatively limited number of zinc(II) 76 
compound classes evaluated as Akt activators so far, we investigated a broader range of 77 
zinc(II) compound families, with the aim of identifying novel and more potent small 78 
molecules that can find applications as chemical perturbagens of Akt signalling and glucose 79 
metabolism. Zinc(II) favorably exhibits low toxicity (especially in comparison to vanadium) 80 
as well as the ability to afford complexes with a variety of coordination geometries, spanning 81 
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from tetra- to hexa-coordination. These properties were taken into account in our compounds 82 
design, along with the inclusion of new phenolic, picolinic, pyridino and hydroxamic ligands, 83 
that we considered likely to contribute favorable properties in terms of functional and 84 
structural diversity, H-bonding ability, aqueous solubility, membrane transport and 85 
pharmacokinetics. The synthesis of eleven new zinc(II) complexes (Figure 2) and their 86 
biological evaluation leading to identification of a potent Akt activator is described herein.  87 
 88 
Figure. 2 Proposed structures of all zinc(II) coordination compounds prepared in this study. 89 
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Results and Discussion 90 
Synthesis of Ligands and Complexes 91 
As part of our effort to discover new and effective metal-based activators of Akt signalling, 92 
we prepared an extended series of zinc(II) complexes, which would be inclusive of a diverse 93 
set of ligands. The compound design had to fit certain requirements: the complexes should 94 
exhibit distinct coordination geometries and 3D-shapes; exhibit various patterns of hydrogen 95 
bond donors and acceptors; be inclusive of pharmaceutically-beneficial functionalities; have 96 
good aqueous solubility and membrane permeability; and be readily synthesized. We chose to 97 
investigate four major classes of ligands, namely phenolic, picolinic (similar to the ones we 98 
previously evaluated with vanadium), pyridino and hydroxamic. The functional groups 99 
present in these ligands were deemed compatible with all of the above criteria, based on their 100 
performance in a multitude of previous pharmaceutical applications. Eleven complexes were 101 
synthesized in total, all of which are novel compounds.  102 
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 103 
Scheme 1. Synthesis of phenolic zinc(II) complexes 1-4 (yields: 1, 99%; 2, 54%; 3, X%; 4, 95%) 104 
The first group of complexes (compounds 1-4, Scheme 1) includes polydentate Schiff base 105 
ligands (or their reduced counterparts) derived from salicyl precursors, and were formed 106 
using Zn(OAc)2 as the metal source. Compounds 1 and 2 exhibit an O-N-O coordination 107 
pattern in their tridentate ligand. Compound 1 was obtained by condensation of glycine on 108 
the 2-position of 2,4-di(formyl)-phenol in the presence of the metal, followed by a second 109 
condensation of the remaining aldehyde moiety to an ethanolamine unit. Complex 2 was 110 
obtained in one step by reacting an α-aminoacid, homocysteic acid, with a similar salicyl 111 
aldehyde that features a sulfonic acid substituent on the 4-position. The chosen polar 112 
functionalities in these compounds confer desired hydrophilicity and H-bonding ability to the 113 
complexes, both beneficial for their aqueous solubility and potential to interact with 114 
biomolecules. As suggested by our study and in agreement with a reported crystal structure of 115 
1a,
[12]
 complexes 1 and 2 were isolated in a hydrated state and in aqueous solution can 116 
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potentially reach hexa-coordination through further hydration. The fact that zinc(II) has no 117 
specific preference for a fixed geometry allows water to occupy free coordination sites, which 118 
is likely the case for other complexes in this study as well. Ligands for the synthesis of 3 and 119 
4 were prepared from the same aromatic precursor as 2. In the case of 3 (which has a ligand-120 
to-metal stoichiometry of 2:1) the organic precursor was modified via reductive amination 121 
with n-propylamine to afford the N-O bidentate amine ligand 3a prior to complexation. The 122 
ligand in 4 (which exhibits an O-N-N-O coordination pattern) links two precursor molecules 123 
via double imine formation upon their condensation with ethylenediamine. The complex 124 
likely has distorted pyramidal geometry, as has been demonstrated previously for other 125 
zinc(II)-salen complexes.
[13]
  126 
 127 
Scheme 2. Synthesis of picolinic zinc(II) complex 5 (yield: 34%) 128 
 129 
Another bidentate N-O ligand was derived from 5-aminopicolinic acid (Scheme 2). Although 130 
this specific complex has not been previously reported, it should be noted that zinc(II) 131 
complexes with other derivatives of picolinic acid have been studied previously as insulin 132 
mimetics.
[14]
  The amine handle was initially modified to afford benzylamine 5a
[15]
 in order to 133 
explore the impact of this bulky moiety on the biological activity of the corresponding 134 
zinc(II) complex. Complex 5 was prepared by reacting the ligand with zinc sulfate under 135 
basic conditions. 136 
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A group of four ligands were derived from 2-formylpyridines (Scheme 3) via imine 137 
formation. In the case of compounds 6b and 7b (ligands for 6 and 7 respectively) the amine 138 
components reacting with 2-formylpyridine contained an ethyl urea moiety. In the synthesis 139 
of 8, propylamine was reacted with 5-nitro-2-formylpyridine, and the nitro/imine 140 
intermediate 8a was reduced to the amine/amine ligand 8b. Complexation to obtain 141 
complexes 6-8 was achieved with ZnSO4. In the case of 9, the zwitterionic amine taurine was 142 
reacted with 2-formylpyridine under basic conditions, followed by complexation with ZnCl2 143 
in the same pot. While this sub-set of molecules also offers extensive H-bonding patterns, 144 
they have larger steric requirements compared with some of the asymmetric members of the 145 
series. 146 
 147 
Scheme 3. Synthesis of pyridino zinc(II) complexes 6-9 (yields: 6, 83%; 7, 51 %; 8, 30%; 9, 20%) 148 
 149 
 150 
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Hydroxamic complexes 10 and 11 were generated as shown in Scheme 4. A benzoic acid 151 
functionalized at the 4-position with an amine handle (either directly attached to the ring or as 152 
an aminomethylene moiety respectively) was converted to its corresponding methyl ester 153 
using known procedures.
[16]
 A critical step in ligand preparation was the transformation of 154 
these esters to hydroxamic acids using hydroxylamine sulfate under basic aqueous conditions. 155 
Conversion of methyl ester 10a to hydroxamic acid 10b was performed in one step
[17]
 leaving 156 
the free amine intact, while 11a underwent modification with Tf2O to form sulphonamide 157 
11b, prior to its conversion to the desired hydroxamic acid 11c. Ligands 10b and 11c 158 
afforded (2:1 ligand-to-metal) complexes upon reaction with Zn(OAc)2. Hydroxamates are 159 
considered excellent chelators for metal ion transport through cell membranes,
[18]
 while both 160 
the hydroxamate
[18]
 and sulphonamide
[19]
 functionalities are of high medicinal relevance and 161 
present in many bioactive compounds.  162 
 163 
Scheme 4. Synthesis of hydroxamic zinc(II) complexes 10-11 (yields: 10, 92%; 11, 84%) 164 
 165 
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 166 
Biological evaluation of the effect of compounds on the Insulin/PI3K/PTEN/Akt 167 
pathway. 168 
Zinc complexes induce Akt activation 169 
The zinc(II) ion and some of its complexes have been reported in the past to elicit activation 170 
of Akt in several cell types.
[11a, 20]
 The activation of Akt in these cases occurs via the PI3K 171 
route and can be monitored by detecting the level of phosphorylation of residue Thr-308 or 172 
Ser-473 of Akt. To examine whether the new zinc complexes prepared in this study induce 173 
Akt activation, NIH3T3 cells were treated with 10 µM of each compound, followed by light 174 
stimulation with 0.04 µM insulin. Western blots were run from the cell lysates and phospho-175 
Akt was quantified using a phospho-Akt (Ser473) antibody. Total Akt was also quantified as 176 
loading control. Figure 3 (A and B) summarizes these results. A positive control (stimulation 177 
with high insulin, 2 µM) and a negative control (low insulin equal to the concentration used 178 
to activate the insulin receptor, 0.04 µM) were included for comparison. All compounds, with 179 
the exception of 1-3 whose effect is negligible, appear to activate Akt by elevating phospho-180 
Akt levels to different extents. While the majority of the compounds exhibit Akt activation to 181 
around 50% of the positive control, the two compounds derived from hydroxamic acid 182 
ligands (10 and 11) stand out, as they appear to perform equally effective or considerably 183 
better than the high insulin activation control respectively.  184 
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 185 
 186 
Figure 3. A (compounds 1-5) and B (compounds 6-11): NIH3T3 cells were starved overnight, 187 
incubated with 10 µM of compound (or vehicle) for 15 min, followed by insulin stimulation as 188 
indicated. Cells were collected and analyzed by western blotting using phospho-Akt (Serine-473) and 189 
Akt antibodies. The blots in Figures 6A and 6B were quantified using ImageJ. The percentage of 190 
activation of Akt (p-Akt phosphorylation normalized for loading using the Akt blotting intensities) is 191 
shown. Low insulin stimulation (0.04 µM) was set to 0% and high insulin stimulation (2 µM) was set 192 
to 100%, respectively. Results (bar chart) are presented as the mean ± standard deviation of three 193 
independent experiments. 194 
 195 
 196 
 197 
Compound 11, as the most promising Akt-activator, was subjected to further investigation. 198 
First, we determined the cytotoxicity of this compound with the MTT assay on NIH3T3 199 
cells.
[21]
 MTT is reduced to formazan by living cells which can be quantified using a 200 
spectrophotometer at an absorbance of 590 nm. As can be seen in Figure 4, compound 11 201 
shows cytotoxicity effects on NIH3T3 cells at concentrations equal or higher than 100 µM. 202 
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At the concentration of 10 µM, which were used in the initial screen of all 11 compounds 203 
(Figure 3), compound 11 has no cytotoxic effect on the cells. 204 
    205 
 206 
Figure 4 Cytotoxicity of compound 11. NIH3T3 cells were treated with up to 1 mM of 207 
compound 11. The results are presented as mean ± standard deviations (n = 4). 208 
 209 
 To determine the minimum concentration of compound 11 required to induce Akt activation, 210 
NIH3T3 cells were treated with various concentrations of the complex. As can be seen in 211 
Figure 5A, Akt activation commenced at a concentration of 500 nM of compound 11. 212 
Moreover, when probing the compound-treated cell lysates for glucogen synthase kinase 3β 213 
(GSK-3β) phosphorylation at Ser-9, we found that 11 was also able to stimulate GSK-3β 214 
phosphorylation with similar potency (Figure 5A). GSK-3β, a key enzyme in the regulation 215 
of glucose metabolism, is phosphorylated at Ser-9 by Akt, suggesting that the activation of 216 
Akt induced by the Zn complexes is propagated downstream of Akt to enhance glycogen 217 
synthesis. For comparison, the effect of compound 11 on the MAP kinase pathway was 218 
investigated by probing cellular extracts for phosphorylation of p42 and p 44 MAP kinases. 219 
As shown in Figure 5B, compound 11 fails to activate MAPK p44/p42 at a concentration of 220 
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500 nM implying that compound 11 might be a useful chemical tool to probe glucose 221 
metabolism and the signalling controlling it.  222 
 223 
Figure 5. (A) Activation of Akt and downstream element GSK-3β (Serine-9) with compound 224 
11 at various concentrations. Starved cells were incubated with 100 nM, 250 nM and 500 nM 225 
of compound 11 for 15 min, followed by stimulation of insulin at a concentration of 0.04 µM. 226 
(B) Compound 11 does not increase phosphorylation levels of p44/p42 MAPK. Same cell 227 
lysates (from figure 5A) were probed with a phospho-p44/42 MAPK (Thr202/Tyr204) 228 
antibody. 229 
    230 
 231 
 232 
Zinc complex-induced Akt activation is PI-3kinase dependent 233 
To investigate whether the observed Akt phosphorylation is PI3K-mediated, we studied the 234 
effects of compound 11 on Akt phosphorylation levels in the presence of LY-294002, a 235 
known PI3K inhibitor.
[22]
 If the observed Akt activation is PI3K dependent, the presence of 236 
LY-294002 would be expected to abolish the activation induced by the zinc compound. 237 
Indeed, use of LY-294002 abrogated the compound 11-induced Akt phosphorylation as 238 
shown in Figure 6. To further confirm the hypothesis that the zinc complex-mediated 239 
activation occurs via PI3K, we examined whether any of the prepared complexes can induce 240 
Akt activation without any insulin stimulation. Notably, when insulin is completely deprived, 241 
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the compounds are unable to induce Akt phosphorylation (Figure 7), which suggests they do 242 
not act directly at the insulin receptor level, but rather between receptor and PI3K. Taking 243 
these observations together, we suggest that the zinc compounds induce Akt activation in a 244 
PI3K-dependent fashion.     245 
 246 
 247 
Figure 6. Effects of compound 11 on Akt phosphorylation with and without the PI3K 248 
inhibitor LY294002.   249 
 250 
 251 
 252 
 253 
 254 
 255 
 256 
 257 
 258 
 259 
 260 
Figure 7. Phospho-Akt (Serine-473) blots after cells were treated either with the zinc 261 
complexes without any insulin stimulation or with insulin (2 µM). Loading control is 262 
performed using the detection of total Akt.  263 
 264 
 265 
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Zinc complex-induced Akt activation is not via inhibition of PTPases or PTEN 266 
The PI3K/Akt cascade is modulated by phosphatases of the PTPase family and PTEN. 267 
PTPases oppose the signalling mediated by receptor tyrosine kinases by removing tyrosine 268 
phosphorylation, whereas PTEN directly antagonises PI3K by dephosphorylating 269 
phosphatidylinositol-3,4,5-trisphosphate (PIP3), the product of PI3K activity. As both 270 
PTPases and PTEN are upstream of Akt, their phosphatase activity can influence the level of 271 
Akt activation. Indeed, it has been found that inhibition of PTPases and PTEN will increase 272 
the cellular activity of Akt.
[23]
  273 
 274 
Zinc(II) has been reported to have the ability to inhibit phosphatases such as λ-275 
phosphoprotein phosphatase,
[24]
 protein tyrosine phosphatase 1B,
[25]
 as well as PTEN.
[11b]
 In 276 
order to investigate whether the observed Akt activation was due to inhibition of PTEN and 277 
PTPases, the two most promising Akt-activating compounds (hydroxamic subset) 10 and 11 278 
were evaluated as PTEN and PTP-β inhibitors in vitro. As shown in Figure 8 the inhibition of 279 
PTP-β and PTEN by compound 10 and 11 revealed a significantly higher potency towards 280 
the PTP-β, but failed to demonstrate the nanomolar potency achieved for Akt 281 
phosphorylation in cellulo. A similar picture was observed for other representative members 282 
of the series (results not shown).  283 
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 284 
 285 
Figure 8. Inhibition of PTEN and PTP-β with zinc(II) complexes 10 and 11 using OMFP and 286 
p-NPP as substrates. Recombinant PTEN and PTP-β were pre-incubated with either 287 
compound 10 or 11 at various concentrations at room temperature. Reactions were initialized 288 
by adding 200 µM of OMFP for PTEN and 1 mM of p-NPP for PTP- β. The IC50 in the 289 
presence of compound 10 was calculated to be 116 ± 25 µM for PTEN and 42 ± 7 µM for 290 
PTP- β. The IC50 of compound 11 was determined to be 77 ± 5 µM for PTEN and 19 ± 1 µM 291 
for PTP-β. The results are presented as the mean ± the standard deviation of three 292 
independent experiments.   293 
 294 
 295 
 296 
Conclusion 297 
 298 
In summary, a series of eleven novel zinc(II) complexes incorporating medicinally-relevant 299 
functionalities were prepared based on phenolic, picolinic, pyridino and hydroxamic ligands. 300 
Screening of the compounds for their potential to upregulate Akt phosphorylation in cellulo, 301 
revealed a sulphonamide-containing hydroxamic complex as a potent activator of Akt at sub-302 
micromolar concentrations. This lead structure can be potentially used as a chemical tool in 303 
diabetes research, due to the fact that apart from activating Akt signalling, its effect is 304 
propagated downstream of Akt towards GSK-3β, an important regulator of glycogen 305 
synthesis/glucose metabolism. Our findings suggest that the observed effects on Akt 306 
phosphorylation by the hydroxamic zinc complexes, while PI3K-mediated, are not due to the 307 
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inhibition of the tumor-supressor phosphatase PTEN or PTPases. This signifies a departure 308 
from other zinc and vanadium complexes that have been shown to cause Akt activation by 309 
inhibiting these phosphatases.  310 
 311 
Future research will be directed towards elucidating the exact mechanism of action of 312 
hydroxamic zinc complexes on Akt activation, as well as the development of improved Akt 313 
activators based on evolution of this novel template.   314 
 315 
Experimental Section 316 
General Procedures 317 
The purity of the organic chemicals was verified by 
1
H-NMR spectroscopy. 
1
H-NMR and 318 
13
C-NMR spectra were recorded on a Bruker Avance 400 MHz Ultrashield NMR 319 
spectrometer. Infra-red spectra were recorded on a Perkin-Elmer FTIR spectrometer. 320 
Electrospray ionisation mass spectra were recorded on a Bruker Daltronics Esquire 3000 321 
spectrometer. Elemental analyses were performed by either London Metropolitan University 322 
or University of Cambridge. The following compounds were prepared following literature 323 
procedures: 1a,
[12]
 5a,
[15]
 10a,
[16a]
 10b
[17]
 and 11a.
[16b]
 324 
 325 
Synthesis 326 
 327 
Synthesis of 1 328 
Intermediate 1a (0.107 g, 0.35 mmol, 1 equiv) was suspended in 45 mL of methanol. 329 
Ethanolamine (42 µL, 0.70 mmol, 2 equiv) was added and the mixture was stirred at r.t. 330 
overnight. The resulting solution was then cooled at 0°C and 2 mL of a methanolic solution 331 
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of NaBH4 (0.026 g, 0.70 mmol, 2 equiv) was added dropwise. The mixture was stirred 332 
initially at 0°C for 1 h, then allowed to warm up to r.t. It was then filtered and the collected 333 
yellow precipitate was washed with methanol and dried to afford 43% of imine intermediate 334 
(0.053 g, 0.15 mmol). This compound was then dissolved in 10 mL of water to afford a clear 335 
solution. Aqueous HCl 0.6 M (0.25 mL, 0.15 mmol, 1 equiv) was added to the solution and 336 
the mixture stirred at r.t. briefly, before evaporating the solvent to dryness. The obtained solid 337 
residue was washed with diethyl ether to afford complex 1 in nearly quantitative yield (0.058 338 
g, 0.15 mmol). 
1
H-NMR (D2O, 4.79 ppm)- (ppm): 3.07 (t, 2H, J=5.4 Hz), 3.75 (t, 2H, J=5.4 339 
Hz), 4.06 (s, 2H), 4.08 (s, 2H), 6.69 (bd, 1H, J=8.6 Hz), 7.24 (m, 2H), 8.26 (s, 1H). 
13
C-NMR 340 
(D2O)- (ppm): 48.1, 50.4, 56.7, 56.8, 119.5, 122.4, 126.0, 135.2, 137.6, 149.9, 168.9. 341 
Elemental analysis: calculated for C12H19ClN2O6Zn: C 37.13, H 4.93, N 7.22; found: C 36.57, 342 
H 4.12, N 6.96.  343 
 344 
Synthesis of 2 345 
Racemic homocysteic acid (0.150 g, 0.82 mmol, 1 equiv) was added to 5 mL of water and the 346 
resulting mixture was heated at 70°C. A solution of 3-formyl-4-hydroxy-benzenesulfonic 347 
acid disodium salt (0.201 g, 0.82 mmol, 1 equiv) in 5 mL of water was then added and the 348 
mixture was stirred at 70 °C for 90 mins. A solution of Zn(OAc)2∙2H2O (0.223 g, 1.02 mmol, 349 
1.24 equiv) in 10 mL of water was finally added. During this last addition the pH of the 350 
solution was adjusted to about 7 with aqueous NaOH 0.5 M. The solution was stirred at 70°C 351 
for two more hours. The solvent was then evaporated to dryness and a yellow-orange residue 352 
was obtained. Successive recrystallizations in water/methanol yielded compound 2 as a white 353 
solid in 54% yield (0.217 g, 0.44 mmol). 
1
H-NMR (D2O, 4.79 ppm)- (ppm): 2.25 (m, 2H), 354 
2.86 (m, 2H), 4.03 (t, 1H, J=6.2 Hz), 6.72 (d, 1H, J1=9.0 Hz), 7.57 (dd, 1H, J1=9.0 Hz, J2= 355 
2.5 Hz), 7.66 (d, 1H, J2=2.5 Hz), 8.38 (s, 1H). 
13
C-NMR (D2O)- (ppm): 29.9, 46.8, 66.3, 356 
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118.4, 122.2, 128.5, 130.9, 133.9, 169.7, 171.1, 179.1. Elemental Analysis: calculated for 357 
C11H13NNa2O11S2Zn∙2H2O: C 24.16, H 3.16, N 2.56; found C 24.42, H 3.33, N 2.54. 358 
 359 
Synthesis of 3a 360 
3-Formyl-4-hydroxy-benzenesulfonic acid disodium salt (0.300g, 1.22 mmol, 1 equiv) was 361 
dissolved in 40 mL of methanol, and propylamine (0.121 mL, 1.47 mmol, 1.2 equiv) was 362 
added. The solution was stirred at r.t. for 3 h, at which point an aliquot was obtained to verify 363 
by NMR that the imine intermediate had formed. The solution was then cooled in an ice-bath 364 
and NaBH4 (0.185 g, 4.88 mmol, 4 equiv) was added. The mixture was stirred at 0°C for 1 h 365 
and at r.t. overnight. A few drops of water were added and then the solvent was evaporated to 366 
dryness. The residue was re-dissolved in methanol and insoluble impurities were removed by 367 
filtration. The filtrate was concentrated under vacuum and diethyl ether was added to 368 
precipitate the product. Compound 3a was obtained as a pink solid in 72% yield (0.255 g, 369 
0.88 mmol). 
1
H-NMR (D2O, 4.79 ppm)- (ppm): 0.85 (t, 3H, J=7.4 Hz), 1.58 (bs, 2H), 2.88 370 
(t, 2H, J=7.4 Hz), 4.02 (s, 2H), 6.55 (d, 1H, J=8.6 Hz), 7.45 (m, 2H). This ligand was used 371 
for the synthesis of 3 without any further purification. 372 
 373 
Synthesis of 3 374 
To a solution of 3a (0.100 g, 0.35 mmol, 1 equiv) in 10 mL of methanol was added a solution 375 
of Zn(OAc)2·2H2O (0.038 g, 0.175 mmol, 0.5 equiv) in 5 mL of methanol and the resulting 376 
mixture was stirred at 50 °C overnight. The solvent was evaporated to dryness and complex 3 377 
was obtained as a yellow residue. It was further purified by recrystallization in 378 
methanol/diethyl ether. 
1
H-NMR (D2O, 4.79 ppm)- (ppm): 0.86 (t, 6H, J=7.1 Hz), 1.59 (bs, 379 
4H), 2.90 (bt, 4H, J=6.7 Hz), 4.06 (s, 4H), 6.63 (d, 2H, J=9.2 Hz), 7.59 (m, 4H). Also 380 
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present: 1 equiv. of NaOAc impurity: 1.82 (s, 3H). Elemental Analysis: calculated for 381 
C20H26N2Na2O8S2Zn∙NaOAc: C 38.86, H 4.30, N 4.12; found: C 38.77, H 4.41, N 3.98.  382 
 383 
Synthesis of 4 384 
A solution of ethylenediamine (0.027 mL, 0.41 mmol, 0.5 equiv) in 2 mL of methanol was 385 
added to a solution of 3-formyl-4-hydroxy-benzenesulfonic acid disodium salt (0.202 g, 0.82 386 
mmol, 1 equiv) in 40 mL of methanol and the reaction mixture was stirred at r.t for 1 h. 387 
Zn(OAc)2·2H2O (0.090 g, 0.41 mmol, 0.5 equiv) was then added and the mixture was heated 388 
at 50°C overnight. It was subsequently filtered, and the collected white residue was washed 389 
with cold methanol and dried under vacuum to afford 4 in 95% yield (0.216 g, 0.39 mmol). 390 
1
H-NMR (D2O, 4.79 ppm)- (ppm): 3.79 (s, 4H),
 
6.80 (d, 2H, J1=8.9 Hz), 7.55 (dd, 2H, 391 
J1=8.9 Hz, J2=2.5 Hz), 7.64 (d, 2H, J2=2.5 Hz), 8.43 (s, 2H).
 13
C-NMR (D2O)- (ppm): 55.8, 392 
119.2, 122.6, 128.3, 130.0, 133.1, 168.1, 170.8. Elemental Analysis: calculated for 393 
C16H14N2Na2O9S2Zn∙0.5H2O: C 34.15, H 2.69, N 4.98; found: C 34.11, H 2.72, N 4.89.
 
 394 
 395 
Synthesis of 5 396 
A solution of ZnSO4·7H2O (0.050 g, 0.175 mmol, 0.5 equiv) in 1.5 mL of water was added to 397 
a solution of 5a (0.080 g, 0.35 mmol, 1 equiv) in 3 mL of EtOH/DMF (1:1). Aqueous NaOH 398 
0.5 M (0.7 mL, 0.35 mmol, 1 equiv) was added and the mixture was stirred at r.t. for 3 h. The 399 
resulting precipitate was then filtered off, washed with water and dried under vacuum to 400 
furnish 34% of complex 5 (0.033 g, 0.06 mmol). 
1
H-NMR (DMSO-d6, 2.50 ppm)- (ppm): 401 
4.34 (d, 4H, J=5.2 Hz), 7.12 (d, 2H, J=7.2 Hz), 7.24 (m, 2H), 7.32 (m, 8H), 7.45 (bs, 2H), 402 
7.85 (d, 2H, J=8.8 Hz), 7.94 (bs, 2H). Elemental Analysis: calculated for C26H26N4O6Zn: C 403 
56.17, H 4.71, N 10.08; found: C 56.18, H 4.60, N 10.14. 404 
 405 
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Synthesis of 6a 406 
Ethyl isocyanate (0.29 mL, 3.66 mmol, 1 equiv) was slowly added to a cooled solution (–10 407 
°C) of 1,3-diaminopropane (0.305 mL, 3.66 mmol, 1 equiv) in 35 mL of CH2Cl2. The mixture 408 
was then allowed to stir overnight at r.t., resulting in precipitation of the desired urea product 409 
(6a). This solid was collected by filtration. Additionally, the filtrate was dried under vacuum 410 
to yield an oily residue, which upon treatment with diethyl ether afforded more of the 411 
product. The combined product was washed with diethyl ether and dried. Overall, 63% of 6a 412 
was obtained (0.335 g, 2.31 mmol).  
1
H-NMR (DMSO-d6, 2.50 ppm)- (ppm): 0.95 (t, 3H, 413 
J=7.0 Hz), 1.40 (m, 2H), 2.50 (m, 2H), 3.05 (m, 4H), 5.80 (bs, 2H). LC-MS (ESI
+
): 414 
calculated for C6H15N3O (M+H) 146.13, found 146.13. This compound was used in the next 415 
step without any further purification. 416 
 417 
Synthesis of 6b 418 
Pyridine-2-carboxaldehyde (0.10 mL, 1.0 mmol, 1 equiv) was slowly added (over 10 min) to 419 
a cold solution (–10 °C) of 6a (0.145 g, 1.0 mmol, 1 equiv) in 2 mL of methanol, and the 420 
mixture was allowed to stir overnight at r.t. The solvent was then removed under vacuum to 421 
yield a white residue, which was washed several times with diethyl ether and dried to furnish 422 
93% of 6b (0.217 g, 0.93 mmol). 
1
H-NMR (DMSO-d6, 2.50 ppm)- (ppm): 0.97 (t, 3H, J=7.2 423 
Hz), 1.73 (m, 2H), 2.98 (m, 2H), 3.05 (apparent q, 2H, J=6.4 Hz), 3.62 (t, 2H, J=6.8 Hz), 424 
5.76 (t, 1H, J=5.6 Hz), 5.86 (t, 1H, J=5.6 Hz), 7.45 (m, 1H), 7.86 (td, 1H, J1=7.6 Hz, J2=1.2 425 
Hz), 8.34 (s, 1H), 8.63 (d, 1H, J=4.8 Hz), 8.94 (d, 1H, J1=7.6 Hz). 
13
C-NMR (DMSO-d6, 426 
39.52 ppm)- (ppm): 16.2, 31.6, 34.5, 37.7, 58.4, 120.9, 125.5, 137.3, 149.8, 154.6, 158.5, 427 
162.4. Elemental Analysis: calculated for C12H18N4O: C 61.52, H 7.74, N 23.91; found: C 428 
61.52, H 7.64, N 23.84.  429 
 430 
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Synthesis of 6 431 
A solution of ZnSO4∙7H2O (0.100 g, 0.35 mmol, 0.5 equiv) in 2 mL of water was added to a 432 
solution of 6b (0.163 g, 0.70 mmol, 1 equiv) in 2 mL of methanol, and the resulting mixture 433 
was stirred at r.t. for 2 h. The solvent was then removed under vacuum, yielding complex 6 as 434 
a pale brown solid in 83% yield (0.193 g, 0.29 mmol). 
 1
H-NMR (DMSO-d6, 2.50 ppm)- 435 
(ppm): 0.88 (t, 6H, J=7.2 Hz), 1.74 (m, 4H), 2.86 (m, 4H), 3.01 (apparent q, 4H, J=5.6 Hz), 436 
3.65 (bs, 4H), 5.85 (bs, 2H), 6.17 (bs, 2H), 7.66 (bs, 2H), 7.94 (d, 2H, J=7.6 Hz), 8.08 (bs, 437 
2H), 8.52 (s, 2H), 8.78 (bs, 2H). Elemental Analysis: calculated for C24H40N8O8SZn·H2O: C 438 
42.14, H 6.19, N 16.38; found: C 42.33, H 5.69, N 16.33. 439 
Synthesis of 7a 440 
This compound was prepared in 28% yield, following an analogous method to the one used 441 
for the synthesis of 6a. 
1
H-NMR (DMSO-d6, 2.50 ppm)- (ppm): 0.95 (t, 3H, J=7.1 Hz), 1.40 442 
(m, 4H), 2.50 (bt, 2H, overlapping with DMSO peak), 3.00 (m, 4H), 5.71 (bt, 1H), 5.80 (bt, 443 
1H). LC-MS (ESI
+
): calculated for C7H17N3O (M+H) 160.15, found 160.15. This compound 444 
was used in the next step without any further purification. 445 
 446 
Synthesis of 7b 447 
This compound was prepared in 99% yield, following an analogous method to the one used 448 
for the synthesis of 6b. 
1
H-NMR (DMSO-d6, 2.50 ppm)- (ppm): 0.96 (t, 3H, J=7.2 Hz), 1.40 449 
(m, 2H), 1.61 (m, 2H), 2.99 (m, 4H), 3.62 (t, 2H, J=7.2 Hz), 5.71 (t, 1H, J=5.6 Hz), 5.80 (t, 450 
1H, J=5.2 Hz), 7.45 (m, 1H), 7.86 (td, 1H, J1=7.6 Hz, J2=1.2 Hz), 7.93 (d, 1H, J1=7.6 Hz), 451 
8.33 (s, 1H), 8.63 (d, 1H, J=4.8 Hz). 
13
C-NMR (DMSO-d6, 39.52 ppm)- (ppm): 16.2, 28.2, 452 
28.4, 34.5, 60.6, 120.8, 125.5, 137.3, 149.8, 154.6, 158.5, 162.1. Elemental Analysis: 453 
calculated for C13H20N4O: C 62.88, H 8.12, N 22.56; found: C 62.96, H 8.09, N 22.48.  454 
  455 
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Synthesis of 7 456 
This compound was prepared in 51% yield, following an analogous method to the one used 457 
for the synthesis of 6. 
1
H-NMR (DMSO-d6, 2.50 ppm)- (ppm): 0.93 (t, 6H, J=7.2 Hz), 1.31 458 
(m, 4H), 1.61 (m, 4H), 2.95 (m, 8H), 3.60 (bs, 4H), 5.93 (bs, 2H), 6.02 (bs, 2H), 7.67 (bs, 459 
2H), 7.97 (d, 2H, J=7.6 Hz), 8.10 (bs, 2H), 8.53 (s, 2H), 8.82 (bs, 2H). Elemental Analysis: 460 
calculated for C26H44N8O8SZn∙2.5H2O: C 42.25, H 6.68, N 15.16; found: C 42.13, H 5.89, N 461 
15.16.  462 
 463 
 464 
Synthesis of 8a 465 
A solution of 5-nitropyridine-2-carboxaldehyde (0.386 g, 2.54 mmol, 1 equiv) in 20 mL of 466 
dry methanol was added dropwise to a solution of propylamine (0.24 mL, 2.92 mmol, 1.15 467 
equiv) in 8mL of methanol. The mixture was stirred for 5 h at r.t. and the solvent was then 468 
removed under vacuum, to afford 8a quantitatively as a dark oil (0.49 g, 2.54 mmol). 
1
H-469 
NMR (CDCl3,7.26 ppm)- (ppm): 1.00 (t, 3H,
 
J=7.4 Hz), 1.79 (apparent sextet, 2H, J=7.2 470 
Hz), 3.73 (td, 2H, J1=6.9 Hz, J2=1.3 Hz), 8.23 (d, 1H, J3=8.7 Hz), 8.47 (bs, 1H), 8.53 (dd, 471 
1H, J3=8.7 Hz, J4=2.4 Hz), 9.47 (d, 1H, J4=2.4 Hz). 
13
C-NMR (CDCl3, 77.00 ppm)- (ppm): 472 
11.9, 23.8, 63.5, 121.21, 131.6, 144.4, 144.9, 159.2, 159.9. This compound was used for the 473 
next step without any further purification.  474 
 475 
Synthesis of 8b 476 
A solution of 8a (0.293 g, 1.52 mmol, 1 equiv) in 25 mL of dry methanol was mixed with 477 
0.09 g of 10% Pd-C and cooled at 5°C. NaBH4 (0.23 g, 6.1 mmol, 4 equiv) was added 478 
portionwise to the mixture over 30 min. The resulting solution was stirred at the same 479 
temperature for 1 h, then allowed to warm up to r.t. It was subsequently filtered through celite 480 
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and the solvent was evaporated to dryness. The remaining residue was re-suspended in ethyl 481 
acetate and the organic phase was washed with water. The aqueous phase was back-extracted 482 
with CHCl3. All organic fractions were dried over MgSO4 and the solvent was evaporated to 483 
dryness to afford 8b as a yellow oil in 55% yield (0.139 g, 0.84 mmol). 
1
H-NMR (CDCl3, 484 
7.26 ppm)- (ppm): 0.93 (m, 3H), 1.54 (m, 2H), 2.61 (m, 2H), 3.66 (bs, 2H), 3.79 (s, 2H), 485 
6.96 (dd, 1H, J1=8.2 Hz, J2= 2.8 Hz), 7.09 (d, 1H, J1=8.2 Hz), 8.06 (d, 1H, J2=2.8 Hz). 
1
H-486 
NMR (DMSO-d6, 2.50 ppm)- (ppm): 0.85 (m, 3H), 1.41 (m, 2H), 2.46 (m, 2H), 3.60 (s, 2H), 487 
5.13 (bs, 2H), 6.88 (dd, 1H, J1’=8.3 Hz, J2’=2.7 Hz), 7.03 (d, 1H, J1’=8.3 Hz), 7.85 (d, 1H, 488 
J2’=2.7 Hz). 
13
C-NMR (CDCl3, 77.00 ppm)- (ppm): 11.8, 23.2, 51.5, 54.7, 122.3, 122.6, 489 
136.9, 141.0, 149.9. 
13
C-NMR (DMSO-d6, 39.52 ppm)- (ppm): 12.3, 22.9, 51.1, 54.4, 121.0, 490 
122.4, 135.8, 143.7, 147.3. This compound was used for the next step without any further 491 
purification.  492 
 493 
Synthesis of 8 494 
A solution of ZnSO4·7H2O (0.121g, 0.42 mmol, 0.5 equiv) in 10 mL of methanol was added 495 
to a solution of 8b (0.139 g, 0.84 mmol, 1 equiv) in 10 mL of methanol, and the resulting 496 
mixture was stirred at r.t. for 3 h. The solvent was then evaporated to dryness and the residue 497 
washed with dichloromethane and ethyl ether. Recrystallization in methanol/diethyl ether 498 
afforded complex 8 as a yellow solid in 30% yield (0.066 g, 0.125 mmol). 
1
H-NMR (DMSO-499 
d6, 2.50 ppm)- (ppm): 0.81 (t, 6H, J=7.3 Hz), 1.50 (m, 4H), 2.62 (bs, 4H), 3.80 (bs, 4H), 500 
5.58 (bs, 2H), 5.71 (bs, 4H), 7.18 (bs, 4H), 8.03 (bs, 2H). 
13
C-NMR (DMSO-d6, 39.52 ppm)-501 
 (ppm): 11.8, 20.9, 50.3, 50.4, 123.3, 123.7, 134.7, 142.4, 145.6. LC-MS (ESI+): calculated 502 
for C18H28N6Zn (M+H) 393.18, found 393.18. IR (cm
-1
): 1118 (SO4
2-
), 1506 (m), 1581 (m), 503 
1630 (m), 1735 (br), 2875 (br), 2964 (br), 3229, 3349. Elemental Analysis: calculated for 504 
C18H34N6O6SZn·2H2O: C 38.33, H 6.79, N 14.90; found: C 38.58, H 6.15, N 14.27.  505 
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 506 
Synthesis of 9 507 
Pyridine-2-carboxaldehyde (0.19 mL, 2 mmol, 1 equiv) was dissolved in 50 mL DMF in a 508 
round-bottom flask. Taurine (0.25 g, 2 mmol, 1 equiv) was added to this solution, followed 509 
by anhydrous triethylamine (0.28 ml, 2 mmol, 1 equiv). After stirring at r.t. until all 510 
components had gone into solution, ZnCl2 was added (0.14 g, 1 mmol, 0.5 equiv) and the 511 
reaction mixture was heated at 110°C for 4h. The resulting precipitate was filtered and 512 
washed to afford 9 as a pink powder in 20% yield (0.10 g, 0.2 mmol). 
1
H-NMR (DMSO-d6, 513 
2.50 ppm)- (ppm): 3.03 (bs, 4H), 4.24 (bs, 4H), 7.67 (t, 2H, J=6.4 Hz), 8.03 (d, 2H, J=8.0 514 
Hz), 8.17 (bs, 2H), 8.36 (bs, 2H), 8.88 (bs, 2H).
 13
C-NMR (DMSO-d6, 39.52 ppm)- (ppm): 515 
49.86, 54.46, 128.94, 141.11, 148.63, 163.60. IR (cm
-1
): 738, 1228, 1530, 1594, 2943, 3235, 516 
3331. Elemental analysis: calculated for C16H18N4O6S2Zn: C 39.07, H 3.69, N 11.39; found: 517 
C 39.13, H 3.73, N 11.45. 518 
 519 
Synthesis of 10 520 
4-Amino-N-hydroxybenzamide (10b) (0.20 g, 1.32 mmol, 1 equiv) was transferred to a 521 
round-bottom flask and dissolved in methanol (13.2 mL). Zn(OAc)2.2H2O (0.145 g, 0.66 522 
mmol, 0.5 equiv) was added, and the reaction was refluxed at 65°C for 12 h, during which a 523 
white precipitate formed. After cooling at r.t., the mixture was filtered and the solid washed 524 
several times with chilled water and dried under vacuum. Overall, 92% (0.235 g, 0.61 mmol) 525 
of complex 10 was obtained. 
1
H-NMR (DMSO-d6, 2.50 ppm)- (ppm): 5.50 (s, 4H), 6.53 (d, 526 
4H, J=8.6 Hz), 7.48 (d, 4H, J=8.6 Hz), 11.50 (s, 2H).
 1
H-NMR (D2O, 4.79 ppm, with 1% 527 
formic acid-d2)- (ppm): 7.26 (d, 4H, J=8.0 Hz), 7.71 (d, 4H, J=8.0 Hz). LC-MS (ESI
+
): 528 
calculated for C14H14N4O4Zn (M+H) 367.04, found 367.04. IR (cm
-1
): 1504, 1563, 1598, 529 
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3018, 3170, 3431. Elemental analysis: calculated for C14H16N4O5Zn: C 43.59, H 4.18, N 530 
14.53; found: C 44.02, H 3.71, N 14.35.  531 
 532 
Synthesis of 11b 533 
Methyl 4-(aminomethyl)benzoate (11a) (1.65 g, 10 mmol, 1 equiv) was transferred to a 534 
round-bottom flask, which was then sealed and purged with nitrogen. Anhydrous CH2Cl2 (33 535 
mL) was added and the mixture was cooled at -78°C. Triethylamine (2.8 mL, 20 mmol, 2 536 
equiv) was added, followed by dropwise addition of trifluoromethanesulfonic anhydride (1.7 537 
mL, 10 mmol, 1 equiv) at -78°C. The mixture was allowed to stir over 3-4 h, with the 538 
temperature slowly rising to 0°C. The reaction mixture was then diluted with CH2Cl2, and 539 
washed once with aqueous NH4Cl (sat), once with aqueous NaCl (sat) and once with H2O. 540 
The organic phase was dried over Na2SO4, then filtered and concentrated under vacuum. The 541 
sample was applied to a silica column and eluted with hexane-ethyl acetate (first 2:1, then 542 
1:1), to afford 11b in 88% yield (2.61 g, 8.8 mmol) as a white solid. 
1
H-NMR (CDCl3, 7.26 543 
ppm)- (ppm): 3.92 (s, 3H), 4.51 (s, 2H), 5.43 (bs, 1H), 7.39 (d, 2H, J=8.3 Hz), 8.01 (d, 2H, 544 
J=8.3 Hz). 
13
C-NMR (CDCl3, 77.00 ppm)- (ppm): 47.65, 52.37, 119.62 (CF3 quartet), 545 
127.61, 130.03, 130.19, 140.49, 166.89. LC-MS (ESI
+
): calculated for C10H10F3NO4S (M+H) 546 
298.04, found 298.04. IR (cm
-1
): 1001, 1018, 1081, 1119, 1150, 1181, 1233, 1289, 1306, 547 
1386, 1445, 1615, 1695, 3229. Elemental analysis: calculated for C10H10F3NO4S: C 40.41, H 548 
3.39, N 4.71; found C 40.51, H 3.27, N 4.64. 549 
 550 
Synthesis of 11c 551 
Hydroxylamine sulfate (0.82 g, 5 mmol, 1 equiv) was transferred to a round-bottom flask 552 
containing 5 g of ice. A solution of NaOH (1.0 g, 25 mmol, 5 equiv) in 5 mL of water was 553 
added to the flask and the mixture was stirred at r.t. for 5 min. A catalytic amount of Na2SO3 554 
 28 
 
(0.095 g, 0.75 mmol, 0.15 equiv) and methyl 4-[(trifluoromethylsulfonamido)methyl]-555 
benzoate (11b) (1.49 g, 5 mmol, 1 equiv) were then added in solid form, and the mixture was 556 
heated at 45°C for 16 h. After cooling at r.t., the pH was modified to about 5 by dropwise 557 
addition of aqueous H2SO4 10% (w/w), and the solvent was removed under vacuum. Cold 558 
methanol was added to the solid residue and the resulting suspension was vigorously stirred 559 
for 15 mins and filtered. The hydroxamic acid, free of most inorganic impurities, was 560 
recovered by drying the methanolic filtrate. This sample was re-dissolved in CH2Cl2-CH3OH 561 
90:10 and applied to a silica column. Elution took place with the same solvent system (first 562 
90:10, then 85:15) to afford 76% (1.13 g, 3.8 mmol) of hydroxamic acid 11c as a white solid. 563 
1
H-NMR (DMSO-d6, 2.50 ppm)- (ppm): 4.42 (s, 2H), 7.40 (d, 2H, J=8.1 Hz), 7.75 (d, 2H, 564 
J=8.1 Hz), 9.04 (s, 1H), 10.02 (s, 1H), 11.22 (s, 1H). 
13
C-NMR (DMSO-d6, 39.52 ppm)- 565 
(ppm): 46.34, 119.69 (CF3 quartet), 127.21, 127.38, 132.20, 140.22, 163.92. LC-MS (ESI
+
): 566 
calculated for C9H9F3N2O4S (M+H) 299.03, found 299.03. IR (cm
-1
): 1511, 1542, 1577, 567 
1618, 3388. Elemental analysis: calculated for C9H9F3N2O4S: C 36.24, H 3.04, N 9.39; found 568 
C 36.25, H 3.02, N 9.11. 569 
 570 
Synthesis of 11 571 
N-hydroxy-4-[(trifluoromethylsulfonamido)methyl]benzamide (0.63 g, 2.11 mmol, 1 equiv) 572 
was transferred to a round-bottom flask and dissolved in absolute ethanol (15 mL). A solution 573 
of NaOH (0.084 g, 2.11 mmol, 1 equiv) in 5 mL of water was added, and the mixture was 574 
stirred at r.t. for 5 min. Solid Zn(OAc)2∙2H2O (0.23 g, 1.055 mmol, 0.5 equiv) was then 575 
added, and the reaction was refluxed at 80°C for 16 h. The solvent was then removed under 576 
vacuum and the solid residue washed extensively with cold water and dried under vacuum to 577 
afford complex 11 in 84% yield (0.60 g, 0.89 mmol), as a white solid.
 1
H-NMR (DMSO-d6, 578 
2.50 ppm)- (ppm): 4.27 (s, 4H), 7.35 (d, 4H, J=7.7 Hz), 7.66 (d, 4H, J=7.7 Hz), 11.82 (s, 579 
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2H). LC-MS (ESI
+
): calculated for C18H16F6N4O8S2Zn (M+H) 658.97, found 658.97. IR (cm
-
580 
1
): 874, 918, 1022, 1056, 1149, 1190, 1231, 1372, 1441, 1503, 1565, 1606, 3350 (br). 581 
Elemental analysis: calculated for C18H18F6N4O9S2Zn.H2O: C 31.07, H 2.90, N 8.05; found C 582 
31.00, H 2.40, N 7.63. 583 
 584 
Biological Materials and Methods 585 
 586 
Cell culture and Western blot analysis 587 
NIH 3T3 fibroblasts were purchased from ATCC. Cells were grown in Dulbecco’s modiﬁed 588 
Eagle’s Medium (DMEM) (Sigma) supplemented with 10% (v/v) bovine calf serum (ATCC) 589 
in an atmosphere of 5% CO2 at 37°C. For testing the zinc complexes, cells were starved in 590 
DMEM (without serum) for 16 h at 37°C. Subsequent to serum deprivation, cells were 591 
treated with zinc compounds for 15 min in DMEM at 37°C. Following compound treatment, 592 
cells were stimulated either with 2 µM or 0.04 µM insulin for 15 min. A control was included 593 
where cells were neither treated with zinc compounds nor stimulated with insulin. The cells 594 
were washed afterwards three times with ice-cold PBS and then scrapped in lysis and SDS-595 
PAGE buffer, containing 150 mM Tris-HCl, pH 6.8, 25% glycerol, 5% SDS, 5% β-596 
mercaptoethanol and 0.01% bromophenol blue. Cell lysates were separated on a 10% SDS- 597 
polyacrylamide gel and transferred onto a nitrocellulose membrane. Membranes were 598 
blocked with 5% skimmed milk in TBS/T (50 mM Tris, 150 mM NaCl, 0.1% Tween 20, pH 599 
7.4) for 1 h at room temperature. Phospho-Akt (Ser473) rabbit monoclonal antibody, mass-600 
Akt rabbit polyclonal antibody, GSK-3β (Ser9) rabbit polyclonal antibody and phospho-601 
p44/42 MAPK (Thr202/Tyr204) rabbit polyclonal antibody (Cell Signaling) were used as 602 
primary antibodies for immunoblotting analysis. Primary antibody incubation was performed 603 
in 5% bovine serum albumin in TBS/T for 16 h at 4°C. Blots were washed for 15 min with 604 
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TBS/T and then incubated with horseradish peroxidase-conjugated secondary antibody 605 
(Biorad) in blocking buffer for 1h and then probed with western blotting detection reagent 606 
(ECL, GE healthcare). 607 
 608 
PTEN expression and purification 609 
PTEN was expressed as a glutathione S-transferase fusion-protein and purified according to 610 
methods previously described.
[26]
 Protein expression was induced in the E. coli strain XL-1 611 
blue for 24 h using 1 mM isopropyl β-D-1-thiogalactopyranoside at 23°C. Cells were 612 
harvested and stored at -20°C.  The harvested cells were re-suspended in lysis buffer 613 
containing 50 mM Tris (pH 7.4), 1% Triton X-100, 10 mM benzamidine hydrochloride, 100 614 
µg/mL soybean trypsin inhibitor, 1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride 615 
hydrochloride and 2 mM dithiothreitol (DTT). Lysis was performed by adding lysozyme to 616 
the cell suspension at a concentration of 2 mg/mL and sonication.  Cell debris was removed 617 
by centrifugation at 18000 g for 1 h at 4°C. The supernatant was loaded onto a glutathione 618 
sepharose column, pre-equilibrated with 50 mM Tris (pH 7.4), 140 mM NaCl and 2.7 mM 619 
KCl. After loading, the column was washed twice with 50 mM Tris (pH 7.4), 140 mM NaCl, 620 
2.7 mM KCl and 2 mM DTT. Another two washes were performed using the same buffer 621 
with 500 mM NaCl. The GST-tagged PTEN was eluted using 20 mM glutathione in 50 mM 622 
Tris (pH 7.4), 250 mM NaCl, 20% glycerol and 2 mM DTT. Protein concentration was 623 
determined using Bradford assay. 624 
 625 
PTEN activity assay 626 
PTEN activity in the presence of zinc compounds was assessed using the fluorescence 627 
substrate 3-O-Methylfluorescein phosphate (OMFP).
[27]
 OMFP was dissolved in DMSO to a 628 
concentration of 20 mM and then further diluted with 1% DMSO to the tested concentrations.  629 
 31 
 
Assays were performed in 100 mM Tris (pH 7.4) containing 2 mM DTT at room temperature 630 
(20 °C). For inhibition studies PTEN was pre-incubated with zinc compounds at RT for 10 631 
min. Reactions were then initialised by adding OMFP to a final concentration of 200 µM. 632 
The hydrolysis of OMFP to OMF was monitored by measuring the change of fluorescence 633 
units (FU) in a 96-well microtiter plate (excitation at 485 nm and emission at 525 nm) using a 634 
Varian fluorescence spectrophotometer. 635 
 636 
Cytotoxicity assay 637 
NIH3T3 cells were seeded into a 96-well plate at a concentration of 8000 cells per well and 638 
incubated at 37 ˚C for 16 hours.  Cells were treated with compound 11 at concentrations 639 
between 10 nM and 1 mM for 2 h at 37˚C (total volume of 100 µL). After 2h, 20 µL of a 5 640 
mg/mL MTT solution were added to each well and incubated for further 4 h at 37˚C. Media 641 
were removed carefully and 150 µL of a 4 mM HCl in isopropyl alcohol were added to each 642 
well and incubated at room temperature for 15min on an orbital shaker. The formation of 643 
formazan by viable cells was measured using a spectrophotometer at 590 nm. 644 
 645 
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